@article{Zhu2026, 
author = {Ying Zhu and Sijie Wang and Huanli Zhou and YiChao Lu and Yitao Zhang and Xuemeng Guo and Qin Lin and Jiaxin Huang and Junlei Zhang and Lihua Luo and Chunqi Zhu and Jian You},
title = {Astragalus polysaccharide loaded MF59 adjuvant system enhances vaccine-induced cellular immune responses},
year = {2026},
journal = {Nano Research},
volume = {19},
number = {8},
pages = {94908705},
keywords = {antitumor, traditional Chinese medicine polysaccharide, nano-adjuvant, cellular immune response, MF59},
url = {https://www.sciopen.com/article/10.26599/NR.2026.94908705},
doi = {10.26599/NR.2026.94908705},
abstract = {Vaccine adjuvants play a pivotal role in enhancing immune responses, but traditional adjuvants such as MF59 primarily induce humoral immunity and exhibit limited ability to activate CD8+ T cell-mediated cellular immunity. To address this critical gap, we strategically integrated Astragalus polysaccharide (APS), a biocompatible and immunomodulatory traditional Chinese medicine-derived polysaccharide, into the MF59 platform to construct a synergistic nano-adjuvant system (AMF59). This rationally designed adjuvant leverages the complementary properties of both components to enhance dendritic cell (DC) activation, facilitate antigen uptake and cross-presentation, and potently boost CD8+ T cell-mediated cellular immunity. In prophylactic tumor challenge studies, the OVA@AMF59 nanovaccine demonstrated potent immunoprotection and significantly suppressed tumor progression. Collectively, this work establishes a rational design strategy for next-generation vaccine adjuvants tailored to applications requiring potent cellular immunity.}
}